Lung Cancer Clinical Trials in Arizona

Showing 341-360 of 533 trials

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

NCT00730639

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

Metastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaMetastatic Melanoma+1 more

Bristol-Myers Squibb395 participantsStarted Oct 2008

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +10 more locations

COMPLETEDPhase 257 miles

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

NCT03322566

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

Lung Cancer

Incyte Corporation233 participantsStarted Jan 2018

Daphne, Alabama, United States • Goodyear, Arizona, United States • Tucson, Arizona, United States +91 more locations

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Lung Cancer Trials in Other Cities

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

PEN-866 in Patients With Advanced Solid Malignancies

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

A Study of LY3023414 in Participants With Advanced Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Safety Study of MGA271 in Refractory Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Other Conditions in Arizona